246 related articles for article (PubMed ID: 35867948)
1. Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
Ossa Gomez CA; Achatz MI; Hurtado M; Sanabria-Salas MC; Sullcahuaman Y; Chávarri-Guerra Y; Dutil J; Nielsen SM; Esplin ED; Michalski ST; Bristow SL; Hatchell KE; Nussbaum RL; Pineda-Alvarez DE; Ashton-Prolla P
JCO Glob Oncol; 2022 Jul; 8():e2200104. PubMed ID: 35867948
[TBL] [Abstract][Full Text] [Related]
2. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
[TBL] [Abstract][Full Text] [Related]
3. Latin American Study of Hereditary Breast and Ovarian Cancer
Oliver J; Quezada Urban R; Franco Cortés CA; Díaz Velásquez CE; Montealegre Paez AL; Pacheco-Orozco RA; Castro Rojas C; García-Robles R; López Rivera JJ; Gaitán Chaparro S; Gómez AM; Suarez Obando F; Giraldo G; Maya MI; Hurtado-Villa P; Sanchez AI; Serrano N; Orduz Galvis AI; Aruachan S; Nuñez Castillo J; Frecha C; Riggi C; Jauk F; Gómez García EM; Carranza CL; Zamora V; Torres Mejía G; Romieu I; Castañeda CA; Castillo M; Gitler R; Antoniano A; Rojas Jiménez E; Romero Cruz LE; Vallejo Lecuona F; Delgado Enciso I; Martínez Rizo AB; Flores Carranza A; Benites Godinez V; Méndez Catalá CF; Herrera LA; Chirino YI; Terrazas LI; Perdomo S; Vaca Paniagua F
Front Oncol; 2019; 9():1429. PubMed ID: 31921681
[No Abstract] [Full Text] [Related]
4. Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.
Lerner-Ellis J; Mighton C; Lazaro C; Watkins N; Di Gioacchino V; Wong A; Chang MC; Charames GS
J Cancer Res Clin Oncol; 2021 Mar; 147(3):871-879. PubMed ID: 32885271
[TBL] [Abstract][Full Text] [Related]
5. Germline Genetic Testing After Cancer Diagnosis.
Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
[TBL] [Abstract][Full Text] [Related]
6. FLABRA, frontline approach for
Giornelli G; Gallardo D; Hegg R; Abuin GG; La Vega M; Lim-Law M; Caceres V; Trujillo L; Pilar Estevez-Diz MD; Pacheco C; Sganga L; Goncalves S
Future Oncol; 2021 May; 17(13):1601-1609. PubMed ID: 33415992
[No Abstract] [Full Text] [Related]
7. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
8. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
[TBL] [Abstract][Full Text] [Related]
9. Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service.
Matta BP; Gomes R; Mattos D; Olicio R; Nascimento CM; Ferreira GM; Brant AC; Boroni M; Furtado C; Lima V; Moreira MÂM; Dos Santos ACE
Sci Rep; 2022 Nov; 12(1):18629. PubMed ID: 36329109
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.
Henkel J; Laner A; Locher M; Wohlfrom T; Neitzel B; Becker K; Neuhann T; Abicht A; Steinke-Lange V; Holinski-Feder E
Eur J Hum Genet; 2023 Aug; 31(8):925-930. PubMed ID: 37188824
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
Chapman-Davis E; Zhou ZN; Fields JC; Frey MK; Jordan B; Sapra KJ; Chatterjee-Paer S; Carlson AD; Holcomb KM
J Gen Intern Med; 2021 Jan; 36(1):35-42. PubMed ID: 32720237
[TBL] [Abstract][Full Text] [Related]
13. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
14. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
16. Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.
Godinez Paredes JM; Rodriguez I; Ren M; Orozco A; Ortiz J; Albanez A; Jones C; Nahleh Z; Barreda L; Garland L; Torres-Gonzalez E; Wu D; Luo W; Liu J; Argueta V; Orozco R; Gharzouzi E; Dean M
Breast Cancer Res Treat; 2024 Jun; 205(3):567-577. PubMed ID: 38520597
[TBL] [Abstract][Full Text] [Related]
17. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
18. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline BRCA1 mutation: a case report.
Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
20. Germline variants of Brazilian women with breast cancer and detection of a novel pathogenic ATM deletion in early-onset breast cancer.
Bandeira G; Rocha K; Lazar M; Ezquina S; Yamamoto G; Varela M; Takahashi V; Aguena M; Gollop T; Zatz M; Passos-Bueno MR; Krepischi A; Okamoto OK
Breast Cancer; 2021 Mar; 28(2):346-354. PubMed ID: 32986223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
